Second, although this study implemented stratified sampling and class weight adjustment to mitigate data imbalance, the limited sample size of HER2-zero breast cancer patients still impacted model robustness, as evidenced by the relatively low NPV in the external validation set of the XGBoost model in Task 1. This evidence concerns the gene ERBB2 and breast carcinoma.